# GRN-1201 With Pembrolizumab in Subjects With Metastatic PD-L1+ NSCLC

Source: https://onco.cc/trials/nct03417882/  
OnCo record `nct03417882` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of GRN-1201 run by BrightPath Biotherapeutics, terminated.

## Summary

GRN-1201 With Pembrolizumab in Subjects With Metastatic PD-L1+ NSCLC is a phase 2 interventional study registered as NCT03417882 by BrightPath Biotherapeutics, with 20 participants enrolled, started 2019-01-03. Conditions recorded: Metastatic NSCLC. Interventions recorded: GRN-1201 + Pembrolizumab.

## Fields

- Kind: Trial
- Status: historic
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03417882
- Phase: 2
- Setting: A Pilot, Open-Label, Multi-Center, Multi-Dose Study of GRN-1201 Added to Pembrolizumab in Subjects With Non-Small Cell Lung Cancer With High PD-L1 Expression
- Sponsor: BrightPath Biotherapeutics
- Enrolled: 20

## Sources

- ClinicalTrials.gov NCT03417882: https://clinicaltrials.gov/study/NCT03417882

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [GRN-1201](https://onco.cc/drugs/grn-1201/)
- companies: [BrightPath Biotherapeutics](https://onco.cc/companies/brightpath-biotherapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct03417882.json